Biogen Inc's stock rose by 4.33%, reaching a 20-day high, as the broader market showed positive momentum with the Nasdaq-100 up 0.54% and the S&P 500 up 0.31%.
The increase in Biogen's stock price is attributed to the joint announcement with Eisai regarding the acceptance of the Biologics License Application for the subcutaneous formulation of LEQEMBI (lecanemab) by China's National Medical Products Administration. This development is expected to enhance medication accessibility for patients and indicates substantial market potential in China, where the number of patients with mild cognitive impairment or mild dementia is projected to rise significantly.
This news not only highlights Biogen's strategic collaboration with Eisai but also positions the company favorably in the Alzheimer's treatment market, potentially driving future sales growth and improving investor sentiment.
Wall Street analysts forecast BIIB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIIB is 186.19 USD with a low forecast of 135.00 USD and a high forecast of 250.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
25 Analyst Rating
Wall Street analysts forecast BIIB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIIB is 186.19 USD with a low forecast of 135.00 USD and a high forecast of 250.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
13 Hold
1 Sell
Moderate Buy
Current: 174.120
Low
135.00
Averages
186.19
High
250.00
Current: 174.120
Low
135.00
Averages
186.19
High
250.00
Citi
Neutral
maintain
$180 -> $185
2026-01-27
New
Reason
Citi
Price Target
$180 -> $185
AI Analysis
2026-01-27
New
maintain
Neutral
Reason
Citi raised the firm's price target on Biogen to $185 from $180 and keeps a Neutral rating on the shares. The firm adjusted targets in the biopharma group as part of a Q4 preview. Estimates that are "beatable" and lower policy risk should create a favorable setup in 2026 for the group, the analyst tells investors in a research note.
Goldman Sachs
Salveen Richter
Buy
maintain
$197 -> $225
2026-01-08
Reason
Goldman Sachs
Salveen Richter
Price Target
$197 -> $225
2026-01-08
maintain
Buy
Reason
Goldman Sachs analyst Salveen Richter raised the firm's price target on Biogen to $225 from $197 and keeps a Buy rating on the shares. After strong sector performance in 2025 driven by market dynamics, easing policy risks, and improving fundamentals, momentum is expected to continue in 2026 as these factors and their secondary effects, such as M&A, persist, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BIIB
Unlock Now
Truist
Hold
maintain
$142 -> $190
2026-01-08
Reason
Truist
Price Target
$142 -> $190
2026-01-08
maintain
Hold
Reason
Truist raised the firm's price target on Biogen to $190 from $142 and keeps a Hold rating on the shares. The firm updated its model, but tells investors in a research note that the fundamental views remain intact from 2025.
Mizuho
Outperform
maintain
$177 -> $207
2026-01-08
Reason
Mizuho
Price Target
$177 -> $207
2026-01-08
maintain
Outperform
Reason
Mizuho raised the firm's price target on Biogen to $207 from $177 and keeps an Outperform rating on the shares. The firm updated the company's model, saying 2026 is "looking a bit better" for Biogen.
About BIIB
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
